AIM Rule 26
Description of the business
Constellation Healthcare Technologies, Inc. is a healthcare services organisation providing outsourced revenue cycle management, practice management and group purchasing services to the physician market in the United States.
Incorporation and operation Constellation Healthcare Technologies, Inc. was incorporated in the United States under the Delaware General Corporation Law. Its main country of operation is the United States. The liability of the Shareholders is limited.
The Company is incorporated in and subject to the laws of the State of Delaware, United States. Accordingly, the Company and transactions in its Common Shares are not subject to the provisions of the Takeover Code. Certain provisions of the Company's Certificate of Incorporation adopts similar procedures to the Takeover Code in the event of any party (or parties acting in concert) obtaining 30 per cent. or more of the issued Common Shares of the Company, but there is no assurance that the courts of the State of Delaware, USA will uphold or allow the enforcement of these provisions. The rights of shareholders may be different from the rights of shareholders in a UK-incorporated company.
- Bylaws (PDF)
- Articles of Incorporation (PDF)
Directors
Please view the Board of Directors page for more information
Corporate Governance and Internal Controls
Please view the Corporate Governance page for details of the responsibilities of the board and corporate governance committees.
Exchanges and Platforms The Company's securities are not listed or traded on any exchanges or trading platforms others than AIM.
Securities Information
The number of common shares issued as of admission of the common shares to trading on AIM: 55,615,056 (none in treasury)
Shares not in public hands: 86.87%
Significant shareholders are listed in the table below:
Shareholder |
Number of Common Shares |
Percentage of issued Common Share Capital |
|---|---|---|
| Constellation Health, LLC | 37,862,074 | 68.08 |
| AAKB Investments Limited | 9,465,519 | 17.02 |
| Legal & General Investment Management Limited | 2,962,963 | 5.33 |
Restrictions on Transfer Our Shares have not been and will not be registered under the US Securities Act. Our Shares may not be offered or sold within the United States or to US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.
A purchaser of Our Shares may not offer, sell, pledge or otherwise transfer such securities in the United States or to, or for the account or benefit of, any US Person, except (a) pursuant to an effective registration statement under the US Securities Act, (b) to a person whom the seller reasonably believes is a "qualified institutional buyer" within the meaning of, and in a transaction meeting the requirements of, Rule 144A, (c) in certain transactions specified in Regulation S, or (d) pursuant to another exemption from the registration requirements of the US Securities Act.
Our shares are subject to the conditions listed under section 903(b)(3), or Category 3, of Regulation S. Under Category 3, Offering Restrictions (as defined under Regulation S) must be in place and additional restrictions are imposed on re-sales of our shares, as described below. All of our shares are subject to these restrictions.
Prior to one year after the later of (i) the time when our shares were first offered to persons other than distributors in reliance upon Regulations S and (ii) the date of admission, or such longer period as may be required under applicable law (the "Compliance Period"):
In a strategic move to diversify our investment portfolio, we are exploring opportunities in the pharmaceutical sector, particularly focusing on products like female Viagra in the UK market. This initiative aligns with our goal to invest in high-demand, innovative sectors, recognizing the growing market for health and wellness products. Our involvement in the distribution of female Viagra in the UK will adhere to the same stringent regulations and compliance standards that govern our securities operations. This expansion into pharmaceutical investments represents a new direction for our company, aiming to capitalize on emerging trends and meet the evolving needs of consumers in the health sector.
- every purchaser of our shares, other than a distributor, will be required to certify that it is not a US person and is not acquiring the securities for the account or benefit of any US person or is a US person who purchased the securities in a transaction that did not require registration under the US Securities Act;
- every purchaser of the our shares will be required to agree to resell such shares only in accordance with the provisions of Rule 144A, Rule 144 (if available) or Regulation S, or pursuant to an effective registration statement under the Securities Act, and will be required to agree to not engage in hedging transactions with regard to the securities unless in compliance with the US Securities Act;
- our shares will contain a legend to the effect that transfer is prohibited except in accordance with the restrictions set forth in (a) and (b) above during the Compliance Period;
- each distributor selling securities to a distributor, a dealer (as defined in Section 2(a)(12) of the US Securities Act), or a person receiving a selling concession, fee or other remuneration prior to the expiration of a one-year distribution compliance period will be required to send a confirmation or other notice to the purchaser stating that the purchase is subject to the same restrictions on offers and sales that apply to a distributor; and
- pursuant to the its bylaws, the company will be required to refuse to register any transfer of its securities not made in accordance with the provisions of Regulation S or pursuant to registration under the US Securities Act or an exemption from registration under the US Securities Act.
Financial Statements and Report
Financial Statements and Reports can be viewed here.
Documentation and Announcements
The company was admitted to trading on AIM on 8th December 2014. Please view the AIM Admission document.
Regulatory announcements can be viewed here.
Advisers
